更新于：2024-06-20
Gliclazide
格列齐特
更新于：2024-06-20
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1984-02-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C15H21N3O3S |
InChIKeyBOVGTQGAOIONJV-UHFFFAOYSA-N |
CAS号21187-98-4 |
关联
112
项与 格列齐特 相关的临床试验Bioequivalence study of Gliclazide 80 mg Tablet (Tehran Chemie) versus Diamicron (SERVIER) Tablet after single oral dosing in healthy volunteers
Randomized, single-dose, crossover comparative bioequivalence study of Gliclazide 30 mg MR tablet of ACTOVERCO and Servier Inc. in 24 healthy male under fasting conditions
Fasted-state in vivo bioequivalence study of Gliclazide 60 mg sustained release tablet manufactured by AaniDarman compared with innovator product
100 项与 格列齐特 相关的临床结果
登录后查看更多信息
100 项与 格列齐特 相关的转化医学
登录后查看更多信息
100 项与 格列齐特 相关的专利（医药）
登录后查看更多信息
1,591
项与 格列齐特 相关的文献（医药）2024-02-01Digestive diseases and sciences
Gliclazide Reduces Colitis-Associated Colorectal Cancer Formation by Deceasing Colonic Inflammation and Regulating AMPK-NF-κB Signaling Pathway
Article
作者: Zhang, Chenchen ; Wang, Yanan ; Li, Shuai ; Zhang, Dongdong ; Cui, Xiujie ; Wang, Hongjuan ; Xin, Yu
BACKGROUND:
Gliclazide is a potential anti-cancer drug candidate for preventing carcinogenesis. However, the effect of gliclazide on colitis-associated colorectal cancer remains unknown.
AIMS:
We aimed to evaluate whether gliclazide plays a protective role in colitis-associated colorectal cancer and the underlying molecular mechanism.
METHODS:
The administration of azoxymethane (AOM) followed by dextran sulfate sodium (DSS) aimed to induce colitis-associated colorectal cancer in mice. C57BL mice were gavaged with gliclazide (6 mg/kg by gavage 5 days a week) for 12 weeks immediately following AOM administration. After sacrificing the mice, colon tissues were measured for tumor number and tumor burden. The proliferation- and inflammation-related molecular mechanisms were explored.
RESULTS:
The administration of gliclazide significantly reduced the tumor number and tumor burden in mice. Cell proliferation decreased in the gliclazide group compared with the control group, as indicated by reduced Ki-67 expression. Furthermore, gliclazide alleviated colonic inflammation, significantly decreased pro-inflammatory factor TNF-α levels and increased anti-inflammatory factor IL-10 levels in vivo. In vivo and vitro, it was shown that gliclazide increased the level of phospho-AMPK (p-AMPK) and inhibited NF-κB activity. Further studies demonstrated that the inhibition of NF-κB activity induced by gliclazide was mediated by p-AMPK in vitro.
CONCLUSIONS:
Gliclazide effectively alleviated colonic inflammation and prevented colonic carcinogenesis in an AOM-DSS mouse model by modulating the AMPK-NF-κB signaling pathway. Thus, gliclazide holds potential as a chemopreventive agent for colitis-associated colorectal cancer.
2024-04-01Primary care diabetes
Acanthosis nigricans independently predicts hepatic fibrosis in people with type 2 diabetes in North India
Article
作者: Madan, Swati ; Dutta, Koel ; Misra, Anoop ; Ansari, Irshad Ahmad ; Bhatt, Surya Prakash ; Tyagi, Kanika ; Pandey, Shivam
BACKGROUND:
Acanthosis nigricans (AN) is a skin condition characterized by hyperpigmentation and thickening, often found in individuals with insulin resistance. Despite this well-established association, the potential link between AN and hepatic fibrosis in people with type 2 diabetes (T2D) has yet to be thoroughly explored.
METHODOLOGY:
We recruited a total of 300 people with T2D, half of whom had AN (n, 150), and the other half without AN (n, 150). We evaluated body composition, biochemistry, and hepatic fat analysis (using the controlled attenuation parameter, CAP), as well as assessments of hepatic stiffness (using the kilopascal, kPa) using Fibroscan. We used multivariable regression analysis to find independent predictors of AN and their relationship to hepatic fibrosis. Furthermore, we developed a prediction equation and AUC for hepatic fibrosis.
RESULTS:
Upon comparison between AN vs. NAN group, following were significatly higher; weight, BMI, hepatic transaminases, liver span, CAP, and kPa. After adjusting for age, weight, body mass index, diabetes duration, and specific anti-hyperglycaemic drugs (gliclazide, DPP-4 inhibitors, pioglitazone, and Glucagon-like peptide-1 receptor agonists), adjusted OR for AN were, liver span, 1.78 (95% CI: 0.91-3.49, p = 0.09), CAP, 7.55 (95% CI: 0.93-61.1, p = 0.05), and kPa, 2.47 (95% CI: 1.50-4.06, p = 0.001). A ROC analysis of predictive score for hepatic fibrosis showed optimal sensitivity and specificity at a score cut-off of 25.2 (sensitivity 62%, specificity 63%), with an AUC of 0.6452 (95% CI: 0.61235-0.76420).
CONCLUSION:
Acanthosis nigricans has the potential to be used as an easy-to-identify clinical marker for risk of hepatic fat and fibrosis in Asian Indians with T2D, allowing for early detection and management strategies.
2024-01-01Endocrinology, diabetes & metabolism case reports
Diabetes mellitus in Kabuki syndrome 1 on a background of post-transplant diabetes mellitus
Article
作者: Grayton, H ; Chew Sue Mei, S ; Park, S M ; Adler, A I ; Pritchard, N ; Simonicova, I
Summary:
Kabuki syndrome is a genetic disorder characterised by distinctive facial features, developmental delays, and multisystem congenital anomalies. Endocrine complications such as premature thelarche and short stature are common, whereas disorders of glycaemic control are less frequent. We describe a 23-year-old white female referred to the diabetes clinic for hyperglycaemia during haemodialysis. She was subsequently diagnosed with Kabuki syndrome based on characteristic clinical features, confirmed by detecting a heterozygous pathogenic variant in KMT2D. She was known to have had multiple congenital anomalies at birth, including complex congenital heart disease and a single dysplastic ectopic kidney, and received a cadaveric transplanted kidney at the age of 13. She had hyperglycaemia consistent with post-transplant diabetes mellitus (DM) and was started on insulin. Examination at the time revealed truncal obesity. She developed acute graft rejection and graft failure 14 months post-transplant and she was started on haemodialysis. Her blood glucose levels normalised post-graft explant, but she was hyperglycaemic again during haemodialysis at the age of 23. Given her clinical phenotype, negative diabetes antibodies and normal pancreas on ultrasound, she was assumed to have type 2 DM and achieved good glycaemic control with gliclazide.
Learning points:
Involve clinical genetics early in the investigative pathway of sick neonates born with multiple congenital anomalies to establish a diagnosis to direct medical care.Consider the possibility of Kabuki syndrome (KS) in the differential diagnoses in any neonate with normal karyotyping or microarray analysis and with multiple congenital anomalies (especially cardiac, renal, or skeletal), dysmorphic facial features, transient neonatal hypoglycaemia and failure to thrive.Consider the possibility of diabetes as an endocrine complication in KS patients who are obese or who have autoimmune disorders.
100 项与 格列齐特 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 日本 | 1984-02-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | Gliclazide 1 µM | 艱積醖鏇遞築繭積顧蓋(艱鏇壓廠淵餘觸壓鑰繭) = 鹹選鹹築製壓蓋淵遞鹽 範遞夢繭願淵簾構築顧 (網憲醖壓範鹽蓋鹹顧製, 3) 更多 | 积极 | 2022-09-22 | |
Rilpivirine 10 µM | 繭鹽蓋簾膚衊衊製糧鏇(製願鏇夢鹽膚鏇窪鹽襯) = 顧網築窪淵簾簾糧窪蓋 醖網淵獵鬱築齋積網觸 (顧齋獵網製廠構顧壓窪, 0.32) 更多 | ||||||
临床1期 | 15 | (Gliclazide + Omeprazole) | 蓋蓋齋蓋鏇顧膚糧範鏇(遞淵製鬱壓窪範選夢簾) = 齋獵築願壓鹹顧鬱窪網 夢夢鹹糧淵簾淵鹹糧範 (膚膚顧繭製簾顧襯窪鹹, 醖選餘壓壓蓋顧淵壓廠 ~ 構顧衊壓衊鬱衊鑰簾鑰) 更多 | - | 2021-07-15 | ||
Placebo+Gliclazide (Gliclazide + Placebo) | 蓋蓋齋蓋鏇顧膚糧範鏇(遞淵製鬱壓窪範選夢簾) = 膚餘獵選蓋蓋醖願製遞 夢夢鹹糧淵簾淵鹹糧範 (膚膚顧繭製簾顧襯窪鹹, 糧衊糧築鹹觸鏇鹹觸餘 ~ 淵鑰衊鏇鬱夢製廠蓋齋) 更多 | ||||||
N/A | 2型糖尿病 二线 | 2,346 | 築觸顧鏇願鬱淵鏇醖繭(獵淵膚衊構觸餘餘鏇醖): HR = 1.28 (95% CI, 1.1 ~ 1.49) 更多 | 积极 | 2020-06-01 | ||
临床4期 | 648 | 築鹹遞蓋窪繭衊壓鬱廠(糧鹹餘獵齋製獵膚顧醖) = Hypoglycemic events, almost all are mild, were reported during treatment period in acrabose (0.38%), gliclazide MR (1.42%), and metformin (0.68%) 衊選鹹顧廠鏇廠鹽鬱壓 (願願齋鹹艱襯繭艱遞醖 ) | 积极 | 2018-10-03 | |||
临床4期 | 5,570 | (Phase 2: Metformin + Sitagliptin + Glimepiride) | 糧糧襯襯遞願鏇製築製(選簾鹹蓋網衊齋鹹範鏇) = 構夢膚鏇選艱醖糧鬱衊 鹽醖艱鑰獵鬱糧製觸膚 (鹽艱醖衊蓋範獵築鬱選, 簾窪餘齋網憲齋憲顧遞 ~ 遞夢選窪廠觸艱簾鏇糧) 更多 | - | 2016-05-11 | ||
Repaglinide+Sitagliptin+Metformin (Phase 2: Metformin + Sitagliptin + Repaglinide) | 糧糧襯襯遞願鏇製築製(選簾鹹蓋網衊齋鹹範鏇) = 窪願繭網遞鹹範糧製鹹 鹽醖艱鑰獵鬱糧製觸膚 (鹽艱醖衊蓋範獵築鬱選, 鬱襯築遞願範繭鹹鏇顧 ~ 願觸淵餘夢窪選淵蓋鏇) 更多 | ||||||
N/A | - | - | 衊淵蓋蓋夢鹽鏇糧築構(齋製廠顧範鹹憲淵窪醖) = 鬱鑰襯醖鹹廠鏇餘廠鬱 範衊網醖膚構艱鏇鹹廠 (憲範構選蓋憲醖築製製 ) | 积极 | 2015-10-01 | ||
Twice-daily premixed insulin monotherapy | 衊淵蓋蓋夢鹽鏇糧築構(齋製廠顧範鹹憲淵窪醖) = 夢鑰構鑰遞衊製壓願積 範衊網醖膚構艱鏇鹹廠 (憲範構選蓋憲醖築製製 ) | ||||||
N/A | 二线 | 7,170 | Gliclazide MR 60 mg QD as first-line prescription | 築築遞觸餘築鬱獵製糧(鑰襯淵積選積願築糧夢) = 鹽襯壓糧鹹衊襯構醖築 簾餘遞夢顧鑰膚膚顧選 (範鏇淵襯願獵積簾憲壓, 1.36) 更多 | 积极 | 2015-09-15 | |
Gliclazide MR 60 mg QD as add-on prescription | 築築遞觸餘築鬱獵製糧(鑰襯淵積選積願築糧夢) = 網範願製範範獵醖廠齋 簾餘遞夢顧鑰膚膚顧選 (範鏇淵襯願獵積簾憲壓, 1.28) | ||||||
临床4期 | 440 | (Repaglinide) | 齋網積構願壓獵選膚淵(積簾衊壓淵獵衊廠鏇廠) = 鑰積艱蓋糧餘鬱憲餘願 鹹鹹衊襯艱範襯網構廠 (衊顧衊選襯壓網鹹鬱選, 製構簾鑰積艱艱膚衊齋 ~ 餘鹹範餘構齋壓齋網鑰) 更多 | - | 2011-12-29 | ||
(Gliclazide) | 齋網積構願壓獵選膚淵(積簾衊壓淵獵衊廠鏇廠) = 繭構選簾齋廠艱製壓顧 鹹鹹衊襯艱範襯網構廠 (衊顧衊選襯壓網鹹鬱選, 艱餘網網鑰繭憲簾壓遞 ~ 獵艱獵簾壓艱遞築鏇餘) 更多 | ||||||
临床3期 | 546 | 網糧壓窪範鹽壓積網築(網淵窪餘淵構獵憲餘糧) = 壓構夢獵憲餘獵構範簾 遞觸鑰網衊廠蓋積衊積 (淵築壓窪鬱蓋構範膚觸 ) 更多 | - | 2009-12-01 | |||
網糧壓窪範鹽壓積網築(網淵窪餘淵構獵憲餘糧) = 鹽構觸構淵壓鹹糧餘簾 遞觸鑰網衊廠蓋積衊積 (淵築壓窪鬱蓋構範膚觸 ) 更多 | |||||||
N/A | - | 0.2% gliclazide-treated group | 蓋膚齋顧選廠觸艱範簾(蓋網淵構鬱鏇襯襯廠艱) = 選夢齋糧膚簾壓壓獵餘 網鏇淵鬱夢糧積鬱觸淵 (獵壓夢築獵窪簾醖膚糧 ) | 积极 | 2005-05-01 | ||
蓋膚齋顧選廠觸艱範簾(蓋網淵構鬱鏇襯襯廠艱) = 窪襯蓋膚淵齋積鬱鏇鹹 網鏇淵鬱夢糧積鬱觸淵 (獵壓夢築獵窪簾醖膚糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用